Palliative Subcutaneous Terbutaline Infusion in Severe Asthma
Sahadevan, A.; Lane, S.J.
Irish Medical Journal 109(5): 410
2016
ISSN/ISBN: 0332-3102 PMID: 27685881 Document Number: 688807
Continuous subcutaneous infusion of terbutaline (CSIT) has been shown to improve asthma control. As an adjunct to standard asthma pharmacotherapy, 3-12mg/day of CSIT can stabilise asthmatic symptoms, reduce hospitalisations and reduce corticosteroid need1,2. Asthmatics who demonstrate a wide diurnal variability in their peak-flows (>40%), termed brittle asthmatics tend to benefit the most from this therapy3. CSIT can have adverse effects and should only be used in specialist respiratory centres.